Enveric Biosciences Inc expected to post a loss of 23 cents a share - Earnings Preview
21/03/2025 12:42
Enveric Biosciences Inc ENVB.OQ ENVB.O is expected to show no change in quarterly revenue when it reports results on March 24 (estimated) for the period ending December 31 2024 LSEG's mean analyst estimate for Enveric Biosciences Inc is for a loss of 23 cents per share. The one available analyst rating on the shares is "buy". The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Enveric Biosciences Inc is $54.80, above its last closing price of $1.73. This summary was machine generated March 21 at 12:42 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Enveric Biosciences
See all newsBrief: Enveric Biosciences Announces Positive Results From IND-Enabling ADMET Studies
Enveric Biosciences Q2 net loss widens
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
Brief: Enveric Biosciences Initiates Investigational New Drug (IND)-Enabling Genotoxicity Studies Of Lead Neuroplastogen Candidate EB-003
Brief: Enveric Biosciences Reports Positive Preclinical Results From Phototoxicity Analysis For Lead Neuroplastogen Candidate Eb-003